Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$190.1KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mahesh V. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.47
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.17
Financials
Revenue
$190.1K-55.6%Net Income
$-2.62MEBITDA
$-2.61MFree Cash Flow
$-3.03MEPS (diluted)
$-0.32Shares Outstanding (diluted)
8.22M+665.3%Operating Expenses
$3.03MCash & Debt
$23.27MReturn of Capital
$0.00Revenue by Segment (annual)
$298.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.98M | $-9.63M | $-1.77 |
| 2024 | $11.20M | $8.4K | $0.00 |
| 2023 | $-2.85M | $-16.35M | $-3.14 |
| 2022 | $500.0K | $-10.76M | $-2.15 |
| 2021 | $16.14M | $-634.4K | $-0.19 |
| 2020 | $0.00 | $-20.96M | $-6.46 |
| 2019 | $165.0K | $-13.01M | $-8.54 |
| 2018 | $428.0K | $-11.66M | $-9.35 |
| 2017 | $0.00 | $-20.98M | $-17.79 |
| 2016 | $0.00 | $-18.97M | $-17.66 |
| 2015 | $0.00 | $-18.21M | $-18.79 |
| 2014 | $0.00 | $-20.37M | $-27.13 |
| 2013 | $0.00 | $-10.59M | $-24.45 |
| 2012 | $7.71M | $3.80M | $14.45 |
Valuation
LPCNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·5h ago·Neutral
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions …
View source ↗ - Newszacks.com·14d ago·Positive
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsprnewswire.com·23d ago·Neutral
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical com…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.39 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.32 vs $-0.40beat
- Thu, May 7$-0.54 vs $-0.51miss
- Mon, Mar 9$-0.34 vs $-0.60beat
- Thu, Nov 6$-0.59 vs $-0.56miss
- Tue, Aug 5$-0.41 vs $-0.41beat
- Thu, May 8$-0.35 vs $-0.35beat
Estimates and results for LPCN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LPCN officers and directors.
- Bought
- $783k
- Sold
- $109k
17 trades
5 trades
- Higuchi John W.bought
- Higuchi John W.bought
- Higuchi John W.bought
- Higuchi John W.bought
- Higuchi John W.bought
- Patel Mahesh V.bought
- Patel Mahesh V.bought
- Patel Mahesh V.bought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LPCN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.